Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clozapine + modafinil
- Development stage
- Phase 4
- Lead developer
- Sandoz
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of clozapine and modafinil represents a drug interaction rather than a single pharmaceutical product. This combination has been studied in clinical settings, particularly for addressing clozapine-induced sedation in schizophrenia patients. Clozapine is an atypical antipsychotic medication primarily used to treat schizophrenia, while modafinil is a wakefulness-promoting agent. When combined, modafinil may increase blood levels of clozapine through the inhibition of cytochrome P450 2C19, potentially leading to clozapine toxicity.
02
Targets
DRD2 (Dopamine D2 Receptor)DRD4 (Dopamine D4 Receptor)DAT (Dopamine plasma membrane transport protein)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on clozapine + modafinil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clozapine + modafinil.